Jump to content

baumer

Wednesday Numbers (MI 8.5 SH2 6.5 Alvin 6.5 TinTin 4.2 DT 4.1)

Recommended Posts

Mission Impossible: 8.5 mill -11.5% (94.6 mill)Sherlock: 6.5 mill -11% (103.5 mill)Alvin: 6.5 -4.5% (69.7 mill)Tin Tin: 4.2 -6.7% (31.8 mill)Dragon Tattoo: 4.1 -11% (36.5 mill)ERC on Twitter

Link to comment
Share on other sites















So where will MI4 end up? It'll pass 100m today; overtake Sherlock soon for the December title, and pass 140m on Monday. January looks seriously weak this year, and it's keeping IMAX screens through the 19th... does the unadjusted franchise record look good? SH2 is mirroring Tron Legacy's numbers at this point. Should be good for 160m+ total.

Edited by Gopher
Link to comment
Share on other sites





So where will MI4 end up? It'll pass 100m today; overtake Sherlock soon for the December title, and pass 140m on Monday. January looks seriously weak this year, and it's keeping IMAX screens through the 19th... does the unadjusted franchise record look good?SH2 is mirroring Tron Legacy's numbers at this point. Should be good for 160m+ total.

I am currently expecting 200-210M for MI4 and 175-185M for SH2.
Link to comment
Share on other sites









So where will MI4 end up? It'll pass 100m today; overtake Sherlock soon for the December title, and pass 140m on Monday. January looks seriously weak this year, and it's keeping IMAX screens through the 19th... does the unadjusted franchise record look good?SH2 is mirroring Tron Legacy's numbers at this point. Should be good for 160m+ total.

MI4 could end up anywhere from 170m - 200m. It all depends on the legs.Sherlock looks like Tron; great comparison. 160m is probably the finish line, for sure.Alvin looks poised for about 130-140m or so.Dragon Tattoo and Tin Tin will finish anywhere from 75-90m. Doubt either can earn the coveted 100m mark. Edited by ravon80
Link to comment
Share on other sites





  • Recently Browsing   0 members

    • No registered users viewing this page.
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use and Guidelines. Feel free to read our Privacy Policy as well.